next glp 1 drug New oral GLP-1 delivers up to 12% weight loss in 36 weeks Drugmakers are only months into

Get the details at ADW Diabetes.

Youve likely heard about glucagon-like peptide-1 agonists commonly referred to as GLP-1 medications, and more widely recognized through pharmaceutical brand names like Ozempic and Mounjaro.

The GLP-1 Receptor Agonist market size reached USD 15.25 Billion in 2024 and is expected to register a revenue CAGR of 21.7%

Glucagon-like peptide-1 (GLP-1) receptor agonists are a newer class of diabetes drugs that have the potential to double as weight loss drugs, widening their lucrative market potentials

NOC= Notice of Compliance.

The emergence of dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor (GLP-1R) co-agonists offers a novel multi-receptor mechanism that can overcome these single-pathway limitations